RARE Ultragenyx Pharmaceutical
- 44.220
- +0.750+1.73%
- 44.220
- 0.0000.00%
Ultragenyx Pharmaceutical News
Wells Fargo Maintains Ultragenyx Pharmaceutical(RARE.US) With Buy Rating, Raises Target Price to $88
Wells Fargo Remains a Buy on Ultragenyx Pharmaceutical (RARE)
Evercore Maintains Ultragenyx Pharmaceutical(RARE.US) With Buy Rating, Maintains Target Price $70
Wells Fargo Maintains Overweight on Ultragenyx Pharmaceutical, Raises Price Target to $88
Ultragenyx Pharmaceutical Analyst Ratings
Analysts Have Conflicting Sentiments on These Healthcare Companies: Ultragenyx Pharmaceutical (RARE), Bicycle Therapeutics (BCYC) and Quest Diagnostics (DGX)
Barclays Maintains Ultragenyx Pharmaceutical(RARE.US) With Buy Rating, Maintains Target Price $81
Analysts Offer Insights on Healthcare Companies: Evolus (EOLS), Ultragenyx Pharmaceutical (RARE) and Henry Schein (HSIC)
TD Cowen Maintains Ultragenyx Pharmaceutical(RARE.US) With Buy Rating, Maintains Target Price $73
TD Cowen Keeps Their Buy Rating on Ultragenyx Pharmaceutical (RARE)
Ultragenyx Pharmaceutical Analyst Ratings
J.P. Morgan Maintains Ultragenyx Pharmaceutical(RARE.US) With Buy Rating, Cuts Target Price to $102
Ultragenyx Pharma Is Maintained at Buy by Canaccord Genuity
Evercore Maintains Ultragenyx Pharmaceutical(RARE.US) With Buy Rating, Maintains Target Price $70
CCORF Maintains Ultragenyx Pharmaceutical(RARE.US) With Buy Rating, Maintains Target Price $121
TD Cowen Maintains Ultragenyx Pharmaceutical(RARE.US) With Buy Rating, Maintains Target Price $73
Stifel Maintains Ultragenyx Pharmaceutical(RARE.US) With Buy Rating, Maintains Target Price $127
TD Cowen Remains a Buy on Ultragenyx Pharmaceutical (RARE)
A Quick Look at Today's Ratings for Ultragenyx Pharmaceutical(RARE.US), With a Forecast Between $70 to $135
Analysts Conflicted on These Healthcare Names: Ultragenyx Pharmaceutical (RARE), Henry Schein (HSIC) and McKesson (MCK)
No Data